Te­va inks $200M glob­al li­cens­ing deal with mi­graine ri­val Alder

Te­va has struck a deal with ri­val mi­graine drug mak­er Alder Bio­Phar­ma­ceu­ti­cals, giv­ing Alder a glob­al li­cense for eptinezum­ab for up to $200 mil­lion in mile­stones plus roy­al­ties.

The glob­al non-ex­clu­sive li­cense, signed by Te­va’s sub­sidiary Te­va Phar­ma­ceu­ti­cals In­ter­na­tion­al GmbH, in­cludes rights to de­vel­op, man­u­fac­ture, and com­mer­cial­ize the drug in the US and world­wide, ex­clud­ing Japan and Ko­rea.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.